Loading clinical trials...
Loading clinical trials...
A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer.
Conditions
Interventions
Azacitidine
Entinostat
+2 more
Locations
5
United States
University of Southern California
Los Angeles, California, United States
Sibley Memorial Hospital
Washington D.C., District of Columbia, United States
Julie Brahmer, MD
Baltimore, Maryland, United States
Julie Brahmer, MD
Baltimore, Maryland, United States
UPMC Cancer Center- Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Start Date
November 6, 2013
Primary Completion Date
April 4, 2023
Completion Date
April 4, 2023
Last Updated
May 3, 2024
NCT07431827
NCT06758401
NCT06427941
NCT06476808
NCT07164313
NCT05142189
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions